“Effect of acid suppression on the effectiveness of phosphate binders in haemodialysis patients”

INTERVENTION: Pantoprazole 40 mg once daily Will be administered as oral capsule for two consecutive six‐week study periods (2 week run in period + 4 week data collection period) making a total of 12 weeks. Two week run in period will be considered after the end of the first 6 week study period before any data collection. CONDITION: Hyperphosphataemia Kidney disease PRIMARY OUTCOME: The difference in mean pre‐dialysis plasma phosphate levels for each patient during the period on and off pantoprazole therapy SECONDARY OUTCOME: Change in serum calcium concentration Change in the mean 7‐point Global Overall Symptom (GOS28) scale. INCLUSION CRITERIA: 1‐ Currently receiving haemodialysis treatment for >1 month at The Queen Elizabeth Hospital, The Royal Adelaide Hospital, or affiliated satellite dialysis units (stable regimen during study period). 2‐ Patient receiving single agent phosphate binders (stable regimen during study period). This include: Calcium Carbonate, Lanthanum Carbonate, Sevelamer hydrochloride, Aluminum Hydroxide.